

# TMS-evoked cortical activity in Parkinson's disease patients

Casula EP<sup>1</sup>, Di Lorenzo F<sup>1</sup>, Stampanoni Bassi M<sup>1,2</sup>, Pellicciari MC<sup>1,3</sup>, Ponzo V<sup>1</sup>, Veniero D<sup>1</sup>, Peppe A<sup>1</sup>, Ponzo V<sup>1</sup>, Brusa L<sup>4</sup>, Stanzione P<sup>3,4</sup>, Caltagirone C<sup>1,3</sup>, Stefani A<sup>3</sup>, Koch G<sup>1,4</sup>



<sup>1</sup> Santa Lucia Foundation, Rome, Italy; <sup>2</sup>San Giovanni di Dio Fatebenefratelli, Brescia, Italy;  
<sup>3</sup>Department of Neurology, Sant'Eugenio Hospital, Rome; <sup>4</sup>Stroke Unit, Policlinico Tor Vergata, Rome, Italy



## Background

The effects of deep brain stimulation of the subthalamic nucleus (DBS-STN) and L-DOPA (LD) on cortical activity in Parkinson's disease (PD) are poorly understood. Previous studies suggested that DBS affects specific intracortical circuits, as revealed by motor-evoked potentials (MEPs) [1,2]. Here, by combining transcranial magnetic stimulation (TMS) and electroencephalography (EEG) we directly explored the effects of STN-DBS, either alone or in combination with LD, on TMS-evoked cortical activity of implanted PD patients.

## Methods

Six advanced PD patients with bilaterally implanted DBS electrodes into the STN were enrolled in the study. All patients were tested in three clinical conditions:

**ON/ON condition:** L-DOPA-ON/DBS-ON;

**OFF/ON condition:** L-DOPA-OFF/DBS-ON;

**OFF/OFF condition:** L-DOPA-OFF/DBS-OFF

Clinical information are reported in **table 1**. TMS pulses were delivered over left M1 while simultaneously acquiring EEG. Eight age-matched healthy volunteers (HC) were tested as a control group.

n	Age	Sex	Disease Duration (y)	Years since surgery	H & Y	UPDRS-III			Therapy	DBS-parameters		
						OFF/OFF	OFF/ON	ON/ON		LE/d	Amplitude (V)	Pulse (µs)
1	72	F	8	3	3	43	37	25	800	R:2-L:1.8	R:60-L:90	R:140-L:140
2	77	M	17	10	3	63	51	33	1100	R:2.5-L:2.5	R:60-L:60	R:180-L:180
3	60	M	14	3	3	55	39	18	600	R:3.5-L:3.5	R:90-L:90	R:185-L:185
4	51	M	13	4	3	66	53	33	650	R:3-L:3	R:60-L:60	R:140-L:140
5	57	M	11	6	3	60	44	32	900	R:3.2-L:3.2	R:60-L:60	R:140-L:140
6	66	F	11	3	2	40	29	17	900	R:3.5-L:3.5	R:60-L:60	R:180-L:180


## Results

### TIME-DOMAIN ANALYSIS


Analysis of global mean field power revealed that STN-DBS (ON/ON and OFF/ON condition) enhanced early GABA<sub>A</sub>-ergic global TMS-evoked activity, i.e. ~45-80 ms after TMS, compared to OFF/OFF condition (**fig. 1A and 1B**). L-DOPA intake (ON/ON condition) produced a further increase of late GABA<sub>B</sub>-ergic TMS-evoked activity, i.e. ~80-130 ms after TMS (**fig. 1B and 1C**), that normalized TMS-evoked activity as compared to HC range of values (**fig. 2**).

### TIME/FREQUENCY-DOMAIN ANALYSIS


Analysis of the TMS-evoked spectral perturbation showed that the combination of STN-DBS and L-DOPA (ON/ON condition) enhanced  $\alpha$  and  $\beta$  TMS-evoked oscillations over central and central-posterior electrodes (**fig. 3**).



**FIG.2 TMS-EVOKED MEAN ACTIVITY**



**FIG.3 TRSP**



## Conclusions

The present data show that STN-DBS, either alone or in association with L-DOPA, induces a remarkable modulation of TMS-evoked cortical activity over M1 in specific time intervals. In agreement with previous studies [1,2], when STN-DBS is applied alone it prompts a selective modulation of early TMS-evoked activity, presumably GABA<sub>A</sub>-mediated [3]. The association with L-DOPA results in additional distinct modulation of later TMS-evoked activity, presumably GABA<sub>B</sub>-mediated [4], whose amplitude was brought to normal range of values (i.e. no difference with HC), and to an enhancement of natural frequencies of M1 (i.e.  $\alpha$  and  $\beta$ ). These findings demonstrate that the two therapies have synergistic effects on M1 activity.